Inspira Enters Quantum Computing Sector, Targeting a Critical Connectivity Bottleneck with Newly Acquired AME Platform
Rhea-AI Summary
Inspira (Nasdaq: IINN) is entering the quantum computing sector by directing its newly acquired additive manufactured electronics (AME) platform toward a 3D connectivity architecture for dilution cryostats. The company says the AME platform, developed with more than $200 million invested, has demonstrated proof of concept for qubit-related device integration.
Inspira intends to change its corporate name to QTREX Ltd. pending shareholder approval and is exploring collaborations while maintaining separate commercialization efforts for its medical products.
Positive
- $200 million invested in AME development to date
- Demonstrated proof of concept for qubit-related device integration
- Targeting a critical cryogenic connectivity bottleneck with 3D AME design
- Plans to rebrand as QTREX to align with quantum focus
Negative
- None.
News Market Reaction – IINN
On the day this news was published, IINN declined 14.78%, reflecting a significant negative market reaction. Argus tracked a peak move of +3.9% during that session. Argus tracked a trough of -11.3% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $21.02M at that time. Trading volume was very high at 3.2x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
IINN is up 6.21% while sector peers show mixed moves: some like IRIX and VVOS are up 4.05–4.64%, others like NMTC and COCH are down around 5–6%. With at least 3 peers moving up, a portion of the move fits broader sector momentum, though today’s news is company-specific.
Previous Acquisition Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 05 | Acquisition term sheet | Positive | +7.8% | Non-binding term sheet for liquid biopsy acquisition plus $15M equity investment. |
| Jan 05 | Acquisition term sheet | Positive | +7.8% | All-share liquid biopsy acquisition framework with $15M strategic investment at $180M valuation. |
Acquisition‑related announcements have previously triggered positive price reactions for IINN.
Recent history shows Inspira using strategic transactions to reposition the business. On Jan 5, 2026, two acquisition‑tagged releases outlined a proposed all‑share liquid biopsy acquisition plus a $15 million equity investment at a $180 million valuation, with $12 million earmarked for legacy technologies. Those events saw about a 7.76% positive move, suggesting the market has reacted constructively to past acquisition pivots.
Historical Comparison
Prior acquisition-tagged news for IINN, focused on liquid biopsy and a $15M investment at a $180M valuation, produced an average move of 7.76%. Today’s acquisition-tagged pivot targets quantum connectivity instead of oncology diagnostics.
Acquisition strategy has shifted from a liquid biopsy diagnostics platform toward leveraging an acquired AME platform for quantum computing connectivity applications.
Regulatory & Risk Context
Inspira has an active Form F-3/A shelf filed on 2025-11-25, allowing offerings of up to $75,000,000 in ordinary shares, warrants, and units. The shelf has been used at least once via a 424B5 prospectus supplement dated 2025-12-15; remaining capacity is not specified in the data.
Market Pulse Summary
The stock dropped -14.8% in the session following this news. A negative reaction despite the strategic quantum pivot would contrast with earlier acquisition-tagged releases that averaged a 7.76% gain. Investors would have weighed the long-term promise of a projected $72 billion quantum market against IINN’s position below its $0.98 200‑day MA and the presence of a $75,000,000 shelf registration, which can shape capital-raising dynamics and sentiment.
Key Terms
dilution cryostats technical
additive manufactured electronics technical
electromagnetic crosstalk technical
qubit coherence technical
fault-tolerant quantum computing technical
liquid biopsy medical
AI-generated analysis. Not financial advice.
- The Company is targeting a new 3D connectivity architecture for use in dilution cryostats, designed to overcome interconnect density limitations, reduce thermal load, and minimize electromagnetic crosstalk and signal noise
- This solution addresses a quantum computing market that McKinsey projects to reach up to
$72 billion by 2035 - Inspira intends to change its corporate name to QTREX Ltd., subject to shareholder approval
RA'ANANA, Israel, April 06, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (“Inspira” or the “Company”) today announced its entry into the quantum computing sector, targeting a critical connectivity bottleneck by directing its recently acquired additive manufactured electronics (“AME”) platform toward a new 3D architecture for systems operating in dilution cryostats.
As quantum computing scales toward larger system architectures, one of the field’s most significant engineering bottlenecks lies in connectivity inside dilution cryostats. In these environments, interconnect density, thermal load, and electromagnetic crosstalk are becoming critical barriers to qubit coherence and system fidelity. Inspira’s AME technology is designed to address these challenges, leveraging differentiated capabilities in 3D design, specialized materials, and precision additive manufacturing to create highly integrated structures that will support quantum system stability, reduce error rates, and accelerate the industry’s path to fault-tolerant quantum computing.
The AME technology, developed over years of intensive research and engineering with more than
This strategic move is driven by Inspira’s Chief Executive Officer, Dagi Ben-Noon, and Inspira’s Chief Operating Officer, Avi Shabtay, the original developers of the AME technology. Notably, Mr. Ben-Noon is one of the founders of Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension”). Their experience is reinforced by leading Inspira personnel across research and development, operations, and finance who previously worked at Nano Dimension. By combining this firsthand knowledge with key members of the existing AME team, whom the Company intends to employ, Inspira anticipates a seamless transition. This continuity is intended to ensure that years of accumulated expertise are fully leveraged.
Quantum computing is expected to represent a market of up to
Dagi Ben-Noon, Chief Executive Officer of Inspira, commented: "As a co-founder of Nano Dimension and a co-inventor and developer of the AME technology, I have an intimate knowledge of its capabilities. Together with our experienced leadership team, we believe we have the expertise needed to adapt AME for cryogenic connectivity in quantum computing. We view this as a technological frontier well matched to the strengths of the AME platform.”
In parallel with its expansion into quantum technologies, Inspira will maintain a dedicated operational focus on advancing the commercialization of its existing medical portfolio. This includes the INSPIRA™ ART100 system and the development of the HYLA™ blood monitoring system as a stand-alone system. The Company remains engaged in ongoing commercial discussions with healthcare systems and strategic partners, managed by a dedicated team to ensure maximum focus without detracting from the new quantum initiatives. Inspira expects these activities to continue as part of its broader strategy as a dedicated subsidiary.
The Company intends to seek shareholder approval to formally change its corporate name to QTREX Ltd. The new name aligns the Company’s corporate identity with its strategic focus on quantum computing connectivity solutions.
The Company has launched a dedicated QTREX website. Investors and industry participants are invited to visit www.q-trex.com to learn more.
About Inspira Technologies
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) is a technology company focused on solving the most critical physical and hardware bottlenecks in quantum computing connectivity. Inspira develops unique quantum connectivity solutions designed for high-density, thermally optimized operation in dilution cryostats, a prerequisite for scaling quantum systems beyond current physical limitations. Additionally, the Company continues to advance its medical technology portfolio, including its respiratory support and blood monitoring platforms under a dedicated business unit. For more information, please visit: www.q-trex.com and www.inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the benefits, advantages and capabilities of AME technology, the potential for its AME business, that it intends to utilize the acquired AME platform to develop unique quantum connectivity solutions designed for high-density, thermally optimized operation in dilution refrigerators and adjacent cryogenic environments, its belief that the AME platform’s 3D design flexibility, specialized materials, and precision additive manufacturing capabilities create a differentiated path toward building application-specific structures, the potential market size for the AME business, its belief that the AME’s prior validation substantiates the platform’s material compatibility and micro-scale precision for quantum hardware applications, and Inspira now intends to leverage these capabilities to address connectivity limitations inside dilution cryostats, that the combined first hand knowledge with key members of the existing AME team, whom Inspira intends to employ, it believes it has secured a seamless transition that is intended to ensure that years of accumulated expertise are fully leveraged, the belief that Inspira has the expertise needed to adapt AME for cryogenic connectivity in quantum computing, which is a technological frontier well matched to the strengths of the AME platform, the belief that the proprietary AME technology gives it a distinct competitive advantage to solve the connectivity and thermal bottlenecks, that it to intends to make its solutions an indispensable link in the global quantum computing value chain, the belief that it has the expertise needed to adapt AME for cryogenic connectivity in quantum computing, its intended development focus, that it intends to maintain dedicated operational focus on advancing the commercialization of its existing medical portfolio, including the INSPIRA™ ART100 system and the development of the HYLA™ blood monitoring system as a stand-alone system, and that it intends to change its corporate name. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at www.sec.gov.
Company Contact
Inspira Technologies
Email: info@inspirao2.com
Phone: +972-9-9664485
Investor Relations Contact
Arx Investor Relations
North American Equities Desk
inspira@arxhq.com
